FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

FDA placed a clinical hold on Atara's ATRA IND applications. Enrollment paused for EBVALLO and ATA3219 clinical studies. GMP compliance issues affect drug production but not all manufacturers. Atara risks suspending CAR-T programs without funding by Q1 2025. Stock down 4.09%, reflecting investor concerns over development setbacks.

US FDA declines to approve Atara Biotherapeutics' cancer therapy

FDA rejected Atara's tabelecleucel cancer therapy application. This will delay potential revenue and development for ATRA.

ATRA

ATRA price chart

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Company intelligence